Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Recommendation of “Buy” by Analysts

Disc Medicine, Inc. (NASDAQ:IRON) has earned an average rating of “Buy” from the eleven analysts that are covering the company, MarketBeat.com reports. Ten analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $93.80.

Several brokerages recently issued reports on IRON. TD Cowen initiated coverage on shares of Disc Medicine in a report on Thursday, February 27th. They set a “buy” rating on the stock. Cantor Fitzgerald boosted their price target on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday. Stifel Nicolaus boosted their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Wedbush reiterated an “outperform” rating and set a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a research report on Tuesday, January 21st.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, CFO Jean M. Franchi sold 3,136 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $171,162.88. Following the completion of the sale, the chief financial officer now owns 69,530 shares in the company, valued at approximately $3,794,947.40. The trade was a 4.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John D. Quisel sold 19,820 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $63.14, for a total transaction of $1,251,434.80. Following the completion of the sale, the chief executive officer now owns 72,065 shares of the company’s stock, valued at approximately $4,550,184.10. The trade was a 21.57 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 346,617 shares of company stock worth $19,182,953. 4.24% of the stock is owned by corporate insiders.

Institutional Trading of Disc Medicine

Institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC grew its stake in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after acquiring an additional 503 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Disc Medicine in the 4th quarter worth $40,000. Tower Research Capital LLC TRC grew its stake in shares of Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after acquiring an additional 266 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Disc Medicine in the 3rd quarter worth $131,000. Finally, Quantbot Technologies LP bought a new stake in shares of Disc Medicine in the 3rd quarter worth $146,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Performance

NASDAQ IRON opened at $53.74 on Thursday. The firm has a 50-day moving average of $55.59 and a 200-day moving average of $56.03. The stock has a market cap of $1.86 billion, a PE ratio of -13.50 and a beta of 0.73. Disc Medicine has a 52-week low of $25.60 and a 52-week high of $68.86.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.08. As a group, analysts predict that Disc Medicine will post -4.07 EPS for the current fiscal year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.